{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:48:21Z","timestamp":1786654101995,"version":"build-2736575974"},"reference-count":241,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017964","name":"Tianjin Municipal Health Commission","doi-asserted-by":"publisher","award":["2023024"],"award-info":[{"award-number":["2023024"]}],"id":[{"id":"10.13039\/100017964","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010882","name":"Tianjin Municipal Education Commission","doi-asserted-by":"publisher","award":["2023ZD033"],"award-info":[{"award-number":["2023ZD033"]}],"id":[{"id":"10.13039\/501100010882","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bcp.2026.118225","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T22:55:39Z","timestamp":1783378539000},"page":"118225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Dysregulation of the bile acid signaling network in non-alcoholic fatty liver disease: Mechanisms and a new paradigm of precision network pharmacology"],"prefix":"10.1016","volume":"252","author":[{"given":"Haoze","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuyao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meihan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxuan","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guixiang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2026.118225_b0005","doi-asserted-by":"crossref","unstructured":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD), Journal of hepatology 81(3) (2024) 492-542.","DOI":"10.1016\/j.jhep.2024.04.031"},{"key":"10.1016\/j.bcp.2026.118225_b0010","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1146\/annurev-pathmechdis-032521-102529","article-title":"Role of the Inflammasome in Liver Disease","volume":"17","author":"de Carvalho Ribeiro","year":"2022","journal-title":"Annu. Rev. Pathol."},{"issue":"10","key":"10.1016\/j.bcp.2026.118225_b0015","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1136\/gutjnl-2017-314307","article-title":"Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD","volume":"67","author":"Jiao","year":"2018","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.bcp.2026.118225_b0020","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.1038\/s41467-023-41061-8","article-title":"Hyodeoxycholic acid ameliorates nonalcoholic fatty liver disease by inhibiting RAN-mediated PPAR\u03b1 nucleus-cytoplasm shuttling","volume":"14","author":"Zhong","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.118225_b0025","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1127743","article-title":"Gut microbiota derived bile acid metabolites maintain the homeostasis of gut and systemic immunity","volume":"14","author":"Su","year":"2023","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118225_b0030","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.apsb.2021.12.011","article-title":"Bile acid coordinates microbiota homeostasis and systemic immunometabolism in cardiometabolic diseases","volume":"12","author":"Guan","year":"2022","journal-title":"Acta pharmaceutica Sinica B"},{"key":"10.1016\/j.bcp.2026.118225_b0035","doi-asserted-by":"crossref","unstructured":"J.S. Fleishman, S. Kumar, Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets, Signal transduction and targeted therapy 9(1) (2024) 97.","DOI":"10.1038\/s41392-024-01811-6"},{"key":"10.1016\/j.bcp.2026.118225_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2020.112775","article-title":"Total alkaloids of Sophora alopecuroides L. ameliorated murine colitis by regulating bile acid metabolism and gut microbiota","volume":"255","author":"Jia","year":"2020","journal-title":"J. Ethnopharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118225_b0045","doi-asserted-by":"crossref","first-page":"901","DOI":"10.3390\/cells11050901","article-title":"Bile Acids: Key Players in Inflammatory Bowel Diseases?","volume":"11","author":"Kriaa","year":"2022","journal-title":"Cells"},{"issue":"9","key":"10.1016\/j.bcp.2026.118225_b0050","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/ibd\/izaa342","article-title":"Alterations in Bile Acid Metabolism Associated with Inflammatory Bowel Disease","volume":"27","author":"Li","year":"2021","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.bcp.2026.118225_b0055","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.1089359","article-title":"The role of bile acid metabolism in the occurrence and development of NAFLD","volume":"9","author":"Bing","year":"2022","journal-title":"Front. Mol. Biosci."},{"issue":"6","key":"10.1016\/j.bcp.2026.118225_b0060","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.3390\/cells10061281","article-title":"Bile Acids Activated Receptors in Inflammatory Bowel Disease","volume":"10","author":"Biagioli","year":"2021","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.bcp.2026.118225_b0065","first-page":"1682","article-title":"Regulation of Hepatocyte Nuclear factor 4\u03b1 Attenuated Lipotoxicity but increased Bile Acid Toxicity in Non-Alcoholic Fatty Liver Disease","volume":"12","author":"Roh","year":"2022","journal-title":"Life (Basel, Switzerland)"},{"issue":"2","key":"10.1016\/j.bcp.2026.118225_b0070","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3390\/nu16020250","article-title":"Gender-specific Bile Acid Profiles in Non-Alcoholic Fatty Liver Disease","volume":"16","author":"Fitzinger","year":"2024","journal-title":"Nutrients"},{"key":"10.1016\/j.bcp.2026.118225_b0075","doi-asserted-by":"crossref","first-page":"7466","DOI":"10.1038\/ncomms8466","article-title":"A metabolic stress-inducible miR-34a-HNF4\u03b1 pathway regulates lipid and lipoprotein metabolism","volume":"6","author":"Xu","year":"2015","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.bcp.2026.118225_b0080","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jhep.2023.12.029","article-title":"TRIB3-TRIM8 complex drives NAFLD progression by regulating HNF4\u03b1 stability","volume":"80","author":"Xiao","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bcp.2026.118225_b0085","doi-asserted-by":"crossref","unstructured":"N. Farooqui, A. Elhence, Shalimar, A Current Understanding of Bile Acids in Chronic Liver Disease, J Clin Exp Hepatol 12(1) (2022) 155-173.","DOI":"10.1016\/j.jceh.2021.08.017"},{"issue":"1","key":"10.1016\/j.bcp.2026.118225_b0090","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cmet.2016.05.005","article-title":"Intestinal Crosstalk between Bile Acids and Microbiota and its Impact on Host Metabolism","volume":"24","author":"Wahlstr\u00f6m","year":"2016","journal-title":"Cell Metab"},{"issue":"11","key":"10.1016\/j.bcp.2026.118225_b0095","first-page":"111618","article-title":"Discovery of farnesoid X receptor and its role in bile acid metabolism","volume":"548","author":"John","year":"2022","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.bcp.2026.118225_b0100","doi-asserted-by":"crossref","unstructured":"A. Di Ciaula, L. Bonfrate, M. Khalil, P. Portincasa, The interaction of bile acids and gut inflammation influences the pathogenesis of inflammatory bowel disease, Internal and emergency medicine 18(8) (2023) 2181-2197.","DOI":"10.1007\/s11739-023-03343-3"},{"issue":"8","key":"10.1016\/j.bcp.2026.118225_b0105","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1152\/physiolgenomics.00011.2021","article-title":"Alterations in bile acid metabolizing gut microbiota and specific bile acid genes as a precision medicine to subclassify NAFLD","volume":"53","author":"Jiao","year":"2021","journal-title":"Physiol. Genomics"},{"key":"10.1016\/j.bcp.2026.118225_b0110","doi-asserted-by":"crossref","first-page":"698852","DOI":"10.3389\/fcimb.2021.698852","article-title":"Disease-Associated Gut Microbiota Reduces the Profile of Secondary Bile Acids in Pediatric Nonalcoholic Fatty Liver Disease","volume":"11","author":"Yu","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118225_b0115","first-page":"266","article-title":"Role of bile acids in inflammatory bowel disease","volume":"31","author":"Tiratterra","year":"2018","journal-title":"Ann. Gastroenterol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118225_b0120","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.chembiol.2024.05.009","article-title":"Chemoproteomic profiling of substrate specificity in gut microbiota-associated bile salt hydrolases","volume":"32","author":"Han","year":"2025","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.bcp.2026.118225_b0125","doi-asserted-by":"crossref","unstructured":"L. Han, A. Pendleton, A. Singh, R. Xu, S.A. Scott, J.A. Palma, P. Diebold, K.P. Malarney, I.L. Brito, P.V. Chang, Chemoproteomic profiling of substrate specificity in gut microbiota-associated bile salt hydrolases, Cell Chemical Biology 32(1) (2025) 145-156.","DOI":"10.1016\/j.chembiol.2024.05.009"},{"issue":"11","key":"10.1016\/j.bcp.2026.118225_b0130","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.3390\/cells10112806","article-title":"Bile Acid Receptors and the Gut-Liver Axis in Nonalcoholic Fatty Liver Disease","volume":"10","author":"Xue","year":"2021","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.bcp.2026.118225_b0135","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41401-022-00880-z","article-title":"Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease","volume":"43","author":"Jiao","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"issue":"5","key":"10.1016\/j.bcp.2026.118225_b0140","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cmet.2013.03.013","article-title":"Pleiotropic roles of bile acids in metabolism","volume":"17","author":"de Aguiar Vallim","year":"2013","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.bcp.2026.118225_b0145","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.cmet.2024.09.008","article-title":"Hepatic FXR-FGF4 is required for bile acid homeostasis via an FGFR4-LRH-1 signal node under cholestatic stress","volume":"37","author":"Song","year":"2025","journal-title":"Cell Metab."},{"issue":"12","key":"10.1016\/j.bcp.2026.118225_b0150","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/jhbp.678","article-title":"Decrease in major secondary bile acid, hyodeoxycholic acid, was the main alteration in hepatic bile acid compositions in a hypertensive nonalcoholic fatty liver disease model","volume":"26","author":"Kodama","year":"2019","journal-title":"J. Hepatobiliary Pancreat. Sci."},{"issue":"12","key":"10.1016\/j.bcp.2026.118225_b0155","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1111\/liv.15030","article-title":"Association between circulating bile acid alterations and nonalcoholic steatohepatitis independent of obesity and diabetes mellitus","volume":"41","author":"Jung","year":"2021","journal-title":"Liver International : Official Journal of the International Association for the Study of the Liver"},{"issue":"12","key":"10.1016\/j.bcp.2026.118225_b0160","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.3390\/biomedicines11123303","article-title":"Decreased FXR Agonism in the Bile Acid Pool is Associated with Impaired FXR Signaling in a Pig Model of Pediatric NAFLD","volume":"11","author":"Maj","year":"2023","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.bcp.2026.118225_b0165","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/apt.16948","article-title":"Circulating bile acid concentrations and non-alcoholic fatty liver disease in Guatemala","volume":"56","author":"Rivera-Andrade","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.bcp.2026.118225_b0170","first-page":"1811","article-title":"Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD, Hepatology (Baltimore","volume":"76","author":"Smirnova","year":"2022","journal-title":"Md.)"},{"key":"10.1016\/j.bcp.2026.118225_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154457","article-title":"Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression","volume":"116","author":"Nimer","year":"2021","journal-title":"Metab. Clin. Exp."},{"issue":"11","key":"10.1016\/j.bcp.2026.118225_b0180","doi-asserted-by":"crossref","DOI":"10.1002\/mnfr.202200636","article-title":"Bile Acid Alterations Characterize the Early Onset and Progression of Nonalcoholic Fatty Liver Disease in Young mice Fed with High Fat and Fructose Diet","volume":"67","author":"Xiang","year":"2023","journal-title":"Mol. Nutr. Food Res."},{"issue":"5","key":"10.1016\/j.bcp.2026.118225_b0185","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/cpt.1699","article-title":"Quantitative Proteomics and Mechanistic Modeling of Transporter-Mediated Disposition in Nonalcoholic Fatty Liver Disease","volume":"107","author":"Vildhede","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.bcp.2026.118225_b0190","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1007\/s00535-015-1148-y","article-title":"The intrahepatic expression levels of bile acid transporters are inversely correlated with the histological progression of nonalcoholic fatty liver disease","volume":"51","author":"Okushin","year":"2016","journal-title":"J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118225_b0195","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000377","article-title":"Alterations in zonal distribution and plasma membrane localization of hepatocyte bile acid transporters in patients with NAFLD","volume":"8","author":"Murphy","year":"2024","journal-title":"Hepatology, Communications"},{"issue":"3","key":"10.1016\/j.bcp.2026.118225_b0200","article-title":"Impact of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) on the expression and function of hepatobiliary transporters: a comprehensive mechanistic review","volume":"1870","author":"Laddha","year":"2024","journal-title":"Biochim. Biophys. Acta"},{"issue":"5","key":"10.1016\/j.bcp.2026.118225_b0205","doi-asserted-by":"crossref","first-page":"G597","DOI":"10.1152\/ajpgi.00310.2017","article-title":"Organic solute transporter OST\u03b1\/\u03b2 is overexpressed in nonalcoholic steatohepatitis and modulated by drugs associated with liver injury, American journal of physiology","volume":"314","author":"Malinen","year":"2018","journal-title":"Gastrointestinal and Liver Physiology"},{"issue":"1","key":"10.1016\/j.bcp.2026.118225_b0210","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1186\/s40001-025-03073-6","article-title":"Nuclear receptors in metabolic, inflammatory, and oncologic diseases: mechanisms, therapeutic advances, and future directions","volume":"30","author":"Abdel-Rasol","year":"2025","journal-title":"Eur. J. Med. Res."},{"issue":"8","key":"10.1016\/j.bcp.2026.118225_b0215","article-title":"Emerging functions of the nuclear receptor LRH-1 in liver physiology and pathology","volume":"1867","author":"Sun","year":"2021","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bcp.2026.118225_b0220","doi-asserted-by":"crossref","first-page":"101094","DOI":"10.1016\/j.plipres.2021.101094","article-title":"Bile acids and their receptors in metabolic disorders","volume":"82","author":"Fiorucci","year":"2021","journal-title":"Prog. Lipid Res"},{"issue":"5","key":"10.1016\/j.bcp.2026.118225_b0225","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000127","article-title":"FXR and NASH: an avenue for tissue-specific regulation","volume":"7","author":"Henry","year":"2023","journal-title":"Hepatology Communications"},{"issue":"5","key":"10.1016\/j.bcp.2026.118225_b0230","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jhep.2023.07.034","article-title":"FXR agonists in NASH treatment","volume":"79","author":"Adorini","year":"2023","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118225_b0235","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s12072-010-9202-6","article-title":"Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease","volume":"4","author":"Yang","year":"2010","journal-title":"Hep. Intl."},{"issue":"4","key":"10.1016\/j.bcp.2026.118225_b0240","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00281-022-00935-7","article-title":"Bile acids and their receptors: modulators and therapeutic targets in liver inflammation","volume":"44","author":"Bertolini","year":"2022","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.bcp.2026.118225_b0245","article-title":"Farnesoid X receptor agonists as broad-acting antivirals: evidence from hepatitis viruses and beyond?","volume":"241","author":"Romain","year":"2025","journal-title":"Antiviral Res."},{"issue":"2","key":"10.1016\/j.bcp.2026.118225_b0250","article-title":"Farnesoid X receptor overexpression prevents hepatic steatosis through inhibiting AIM2 inflammasome activation in nonalcoholic fatty liver disease","volume":"1870","author":"Xu","year":"2024","journal-title":"Biochim. Biophys. Acta"},{"issue":"1","key":"10.1016\/j.bcp.2026.118225_b0255","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12876-018-0805-z","article-title":"Response of fibroblast growth factor 19 and bile acid synthesis after a body weight-adjusted oral fat tolerance test in overweight and obese NAFLD patients: a non-randomized controlled pilot trial","volume":"18","author":"Friedrich","year":"2018","journal-title":"BMC Gastroenterol."},{"issue":"8","key":"10.1016\/j.bcp.2026.118225_b0260","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1038\/s41401-024-01276-x","article-title":"Liver receptor homolog-1: structures, related diseases, and drug discovery","volume":"45","author":"Wu","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bcp.2026.118225_b0265","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.trsl.2016.06.003","article-title":"Genomics of human fatty liver disease reveal mechanistically linked lipid droplet-associated gene regulations in bland steatosis and nonalcoholic steatohepatitis","volume":"177","author":"Sahini","year":"2016","journal-title":"Translational Research : the Journal of Laboratory and Clinical Medicine"},{"issue":"2","key":"10.1016\/j.bcp.2026.118225_b0270","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1172\/JCI85499","article-title":"Impaired SUMOylation of nuclear receptor LRH-1 promotes nonalcoholic fatty liver disease","volume":"127","author":"Stein","year":"2017","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.bcp.2026.118225_b0275","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/s12944-025-02720-5","article-title":"Nitroxoline mitigates hepatic steatosis by enhancing cholesterol efflux and promoting bile acid synthesis through LRH-1 signaling","volume":"24","author":"Liu","year":"2025","journal-title":"Lipids Health Dis."},{"issue":"2","key":"10.1016\/j.bcp.2026.118225_b0280","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.apsb.2023.11.011","article-title":"Mechanism of action of the bile acid receptor TGR5 in obesity","volume":"14","author":"Lun","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bcp.2026.118225_b0285","doi-asserted-by":"crossref","unstructured":"John, Y. L. Chiang, Preeti, Pathak, Hailiang, Liu, Ajay, C. Donepudi, Jessica, M. Ferrell, Shannon, Boehme, Intestinal Farnesoid X Receptor and Takeda G Protein Couple Receptor 5 Signaling in Metabolic Regulation, Digestive Diseases 35(3) (2017) 241-245.","DOI":"10.1159\/000450981"},{"issue":"1","key":"10.1016\/j.bcp.2026.118225_b0290","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41392-024-01811-6","article-title":"Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets","volume":"9","author":"Fleishman","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bcp.2026.118225_b0295","article-title":"TGR5 Regulates Macrophage Inflammation in Nonalcoholic Steatohepatitis by Modulating NLRP3 Inflammasome Activation","volume":"11","author":"Shi","year":"2020","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118225_b0300","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1172\/JCI64551","article-title":"The TGR5 receptor mediates bile acid-induced itch and analgesia","volume":"123","author":"Alemi","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2026.118225_b0305","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/7659509","article-title":"Role of Bile Acids in Dysbiosis and Treatment of Nonalcoholic Fatty Liver Disease","volume":"2019","author":"Wang","year":"2019","journal-title":"Mediators Inflamm."},{"issue":"9","key":"10.1016\/j.bcp.2026.118225_b0310","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.3390\/nu13093143","article-title":"Bile Acid-Gut Microbiota Axis in Inflammatory Bowel Disease: from Bench to Bedside","volume":"13","author":"Yang","year":"2021","journal-title":"Nutrients"},{"issue":"11","key":"10.1016\/j.bcp.2026.118225_b0315","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1080\/14728222.2023.2274099","article-title":"Vitamin D\/vitamin D receptor pathway in non-alcoholic fatty liver disease","volume":"27","author":"Liu","year":"2023","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.bcp.2026.118225_b0320","doi-asserted-by":"crossref","unstructured":"T.G. Li, John, Y. L. Chiang, Bile Acid Signaling in Metabolic and Inflammatory Diseases and Drug Development, Pharmacological reviews 76(6) (2024) 1221-1253.","DOI":"10.1124\/pharmrev.124.000978"},{"issue":"24","key":"10.1016\/j.bcp.2026.118225_b0325","doi-asserted-by":"crossref","first-page":"11897","DOI":"10.3390\/ijms262411897","article-title":"Gut Microbiota in the Regulation of Intestinal Drug Transporters: Molecular Mechanisms and Pharmacokinetic Implications","volume":"26","author":"Rzeczycki","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.bcp.2026.118225_b0330","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1007\/s00204-014-1348-x","article-title":"Pregnane X receptor activation and silencing promote steatosis of human hepatic cells by distinct lipogenic mechanisms","volume":"89","author":"Bitter","year":"2015","journal-title":"Arch. Toxicol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118225_b0335","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.3390\/biomedicines13061422","article-title":"Orchestration of Gut-Liver-Associated Transcription Factors in MAFLD: from Cross-Organ Interactions to Therapeutic Innovation","volume":"13","author":"Liu","year":"2025","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.bcp.2026.118225_b0340","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ajpath.2025.04.015","article-title":"Cholestasis in Alcohol-Associated Liver Disease","volume":"196","author":"Yan","year":"2026","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118225_b0345","doi-asserted-by":"crossref","first-page":"21642","DOI":"10.1038\/s41598-024-72561-2","article-title":"Liver-specific Coxsackievirus and adenovirus receptor deletion develop metabolic dysfunction-associated fatty liver disease","volume":"14","author":"Kim","year":"2024","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.bcp.2026.118225_b0350","doi-asserted-by":"crossref","first-page":"12980","DOI":"10.3168\/jds.2021-20596","article-title":"Liver X receptor \u03b1 promotes milk fat synthesis in buffalo mammary epithelial cells by regulating the expression of FASN","volume":"104","author":"Zhang","year":"2021","journal-title":"J. Dairy Sci."},{"key":"10.1016\/j.bcp.2026.118225_b0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2019.108794","article-title":"Acanthoic acid modulates lipogenesis in nonalcoholic fatty liver disease via FXR\/LXRs-dependent manner","volume":"311","author":"Han","year":"2019","journal-title":"Chem. Biol. Interact."},{"issue":"24","key":"10.1016\/j.bcp.2026.118225_b0360","doi-asserted-by":"crossref","first-page":"17304","DOI":"10.3390\/ijms242417304","article-title":"Berberine Protects against High-Energy and Low-Protein Diet-Induced Hepatic Steatosis: Modulation of Gut Microbiota and Bile Acid Metabolism in Laying hens","volume":"24","author":"Wang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.bcp.2026.118225_b0365","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1016\/j.ajpath.2018.07.028","article-title":"Angiopoietin-like Protein 8 is a Novel Vitamin D Receptor Target Gene involved in Nonalcoholic Fatty Liver Pathogenesis","volume":"188","author":"Garc\u00eda-Monz\u00f3n","year":"2018","journal-title":"Am. J. Pathol."},{"issue":"12","key":"10.1016\/j.bcp.2026.118225_b0370","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1074\/jbc.RA119.011487","article-title":"Vitamin D receptor targets hepatocyte nuclear factor 4\u03b1 and mediates protective effects of vitamin D in nonalcoholic fatty liver disease","volume":"295","author":"Zhang","year":"2020","journal-title":"J. Biol. Chem."},{"issue":"7857","key":"10.1016\/j.bcp.2026.118225_b0375","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41586-021-03421-6","article-title":"CAR directs T cell adaptation to bile acids in the small intestine","volume":"593","author":"Chen","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118225_b0380","doi-asserted-by":"crossref","unstructured":"A.J. Lickteig, Y.C. Zhang, C.D. Klaassen, I.L. Csanaky, Effects of Absence of Constitutive Androstane Receptor (CAR) on Bile Acid Homeostasis in Male and Female Mice, Toxicological Sciences 171(1) (2019) 132-145.","DOI":"10.1093\/toxsci\/kfz143"},{"key":"10.1016\/j.bcp.2026.118225_b0385","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvad114.1744","article-title":"SAT006 Activation of the CAR\/RXR Heterodimer by Pesticides and Induced Metabolic Effects","volume":"7","author":"Dauwe","year":"2023","journal-title":"J. Endocr. Soc."},{"key":"10.1016\/j.bcp.2026.118225_b0390","unstructured":"L. Voilquin, T.Y. Liu, Y. Jung, Nikki, P. Taylor, Meng, Zhao, Gregory, W. Charville, Silas Boye, Nissen, Hannele, Yki\u2010J\u00e4rvinen, Russ, B. Altman, Katrin, J. Svensson, Single-cell analysis of non-alcoholic fatty livers identifies a role for the constitutive androstane receptor, bioRxiv (Cold Spring Harbor Laboratory) (2022)."},{"issue":"12","key":"10.1016\/j.bcp.2026.118225_b0395","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1124\/dmd.111.041012","article-title":"Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease","volume":"39","author":"Hardwick","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2026.118225_b0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154925","article-title":"Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease","volume":"126","author":"Negi","year":"2022","journal-title":"Metab. Clin. Exp."},{"key":"10.1016\/j.bcp.2026.118225_b0405","doi-asserted-by":"crossref","unstructured":"G.A. Macdonald, J.B. Prins, Peroxisomal fatty acid metabolism, peroxisomal proliferator-activated receptors and non-alcoholic fatty liver disease, Journal of Gastroenterology and Hepatology 19(12) 2004 1335-1337.","DOI":"10.1111\/j.1440-1746.2004.03562.x"},{"issue":"12","key":"10.1016\/j.bcp.2026.118225_b0410","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1111\/1750-3841.15951","article-title":"Policosanol alleviates hepatic lipid accumulation by regulating bile acids metabolism in C57BL6\/mice through AMPK-FXR-TGR5 cross-talk","volume":"86","author":"Zhai","year":"2021","journal-title":"J. Food Sci."},{"key":"10.1016\/j.bcp.2026.118225_b0415","article-title":"Mogroside V Protects against Hepatic Steatosis in mice on a High-Fat Diet and LO2 Cells Treated with Free Fatty Acids via AMPK Activation","volume":"2020","author":"Li","year":"2020","journal-title":"Evid. Based Complement. Alternat. Med."},{"issue":"50","key":"10.1016\/j.bcp.2026.118225_b0420","doi-asserted-by":"crossref","first-page":"47154","DOI":"10.1074\/jbc.M107000200","article-title":"Antagonism of the actions of peroxisome proliferator-activated receptor-alpha by bile acids","volume":"276","author":"Sinal","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.bcp.2026.118225_b0425","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1097\/HEP.0000000000000182","article-title":"Hepatic fibrosis: targeting peroxisome proliferator-activated receptor alpha from mechanism to medicines","volume":"78","author":"Gong","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.bcp.2026.118225_b0430","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(23)02147-5","article-title":"Peroxisome proliferator-activated receptor alpha and estrogen related receptor alpha ligand combinations ameliorate non-alcoholic fatty liver disease","author":"Antwi","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bcp.2026.118225_b0435","doi-asserted-by":"crossref","unstructured":"M.A. Bromke, M. Krzystek\u2212Korpacka, Bile Acid Signaling in Inflammatory Bowel Disease, International Journal of Molecular Sciences 22(16) (2021) 9096.","DOI":"10.3390\/ijms22169096"},{"key":"10.1016\/j.bcp.2026.118225_b0440","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2022.816836","article-title":"Lactobacillus casei Strain Shirota Ameliorates Dextran Sulfate Sodium-Induced Colitis in mice by increasing Taurine-Conjugated Bile Acids and Inhibiting NF-\u03baB Signaling via Stabilization of I\u03baB\u03b1","volume":"9","author":"Wong","year":"2022","journal-title":"Front. Nutr."},{"issue":"8049","key":"10.1016\/j.bcp.2026.118225_b0445","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41586-024-08379-9","article-title":"Host metabolism balances microbial regulation of bile acid signalling","volume":"638","author":"Won","year":"2025","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.bcp.2026.118225_b0450","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41564-023-01570-0","article-title":"Gut commensal Christensenella minuta modulates host metabolism via acylated secondary bile acids","volume":"9","author":"Liu","year":"2024","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.bcp.2026.118225_b0455","doi-asserted-by":"crossref","unstructured":"D.J. Parks, S.G. Blanchard, R.K. Bledsoe, G. Chandra, T.G. Consler, S.A. Kliewer, J.B. Stimmel, T.M. Willson, A.M. Zavacki, D.D. Moore, J.M. Lehmann, Bile acids: natural ligands for an orphan nuclear receptor, Science (New York, N.Y.) 284(5418) (1999) 1365-8.","DOI":"10.1126\/science.284.5418.1365"},{"issue":"5","key":"10.1016\/j.bcp.2026.118225_b0460","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1097-2765(00)80348-2","article-title":"Endogenous bile acids are ligands for the nuclear receptor FXR\/BAR","volume":"3","author":"Wang","year":"1999","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bcp.2026.118225_b0465","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/164_2019_236","article-title":"Bile Acid-Activated Receptors: a Review on FXR and Other Nuclear Receptors","volume":"256","author":"Shin","year":"2019","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118225_b0470","article-title":"Regulation of gut microbiota-bile acids axis by probiotics in inflammatory bowel disease","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118225_b0475","first-page":"34","article-title":"Targeting nuclear receptors for NASH\/MASH: from bench to bedside","volume":"8","author":"Sinha","year":"2024","journal-title":"Liver Research (Beijing, China)"},{"key":"10.1016\/j.bcp.2026.118225_b0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhazmat.2024.135480","article-title":"Vitamin D receptor attenuates carbon tetrachloride-induced liver fibrosis via downregulation of YAP","volume":"478","author":"Wang","year":"2024","journal-title":"J. Hazard. Mater."},{"key":"10.1016\/j.bcp.2026.118225_b0485","unstructured":"X.L. LI, F.X. Sun, Z.M. Shang , Y.X. Zhang, J. Lin, Q.X. Zhang, Effect of Dangfei Liganning capsule on liver X receptor \u03b1\/steroid regulatory element binding protein-1\/fatty acid synthase signal pathway in rats with metabolic- associated fatty liver disease, Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan 42(6) (2022) 940-947."},{"issue":"8","key":"10.1016\/j.bcp.2026.118225_b0490","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.3390\/ph17081073","article-title":"Unlocking Cholesterol Metabolism in Metabolic-Associated Steatotic Liver Disease: Molecular Targets and Natural Product Interventions","volume":"17","author":"Li","year":"2024","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"key":"10.1016\/j.bcp.2026.118225_b0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2022.08.008","article-title":"Xie, Hepatic cytochrome P450 8B1 and cholic acid potentiate intestinal epithelial injury in colitis by suppressing intestinal stem cell renewal","author":"Chen","year":"2022","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.bcp.2026.118225_b0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155720","article-title":"The ubiquitin-like modifier FAT10 is induced in MASLD and impairs the lipid-regulatory activity of PPAR\u03b1","volume":"151","author":"Clavreul","year":"2024","journal-title":"Metab. Clin. Exp."},{"key":"10.1016\/j.bcp.2026.118225_b0505","doi-asserted-by":"crossref","unstructured":"P. Pathak, H.L. Liu, S. Boehme, C. Xie, Kristopher, W. Krausz, J. Frank, G. John, Y. L. Chiang, Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism, Journal of Biological Chemistry 292(26) (2017) 11055-11069.","DOI":"10.1074\/jbc.M117.784322"},{"key":"10.1016\/j.bcp.2026.118225_b0510","doi-asserted-by":"crossref","unstructured":"C. Handschin, U. Meyer, Regulatory network of lipid-sensing nuclear receptors: roles for CAR, PXR, LXR, and FXR, Archives of Biochemistry and Biophysics 433(2) (2005) 387-396.","DOI":"10.1016\/j.abb.2004.08.030"},{"issue":"1","key":"10.1016\/j.bcp.2026.118225_b0515","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/aps.2014.116","article-title":"Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis","volume":"36","author":"Jiao","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bcp.2026.118225_b0520","doi-asserted-by":"crossref","unstructured":"L. He, J. Wu, Y. Wang, Y. Jiao, F. Zhang, Z. Lin, Q. Liu, Y. Feng, Vitamin D 3 Metabolite-Enhanced Hepatic VDR-FXR Binding Attenuates Bile Acid Dysregulation-Induced Diarrhea in Weaned Piglets, Journal of agricultural and food chemistry 74(15) (2026) 12069-12086.","DOI":"10.1021\/acs.jafc.5c14694"},{"key":"10.1016\/j.bcp.2026.118225_b0525","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1011994","article-title":"Role of bile acids in overweight and obese children and adolescents","volume":"13","author":"Giannini","year":"2022","journal-title":"Front. Endocrinol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118225_b0530","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1124\/mol.110.064618","article-title":"A functional cross-talk between liver X receptor-\u03b1 and constitutive androstane receptor links lipogenesis and xenobiotic responses","volume":"78","author":"Zhai","year":"2010","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118225_b0535","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1038\/s41467-025-56642-y","article-title":"The hypolipidemic effect of MI-883, the combined CAR agonist\/ PXR antagonist, in diet-induced hypercholesterolemia model","volume":"16","author":"Dusek","year":"2025","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.bcp.2026.118225_b0540","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.3390\/cells9112395","article-title":"Regulation of CAR and PXR Expression in Health and Disease","volume":"9","author":"Daujat-Chavanieu","year":"2020","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.bcp.2026.118225_b0545","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1016\/j.apsb.2024.04.027","article-title":"The role of botanical triterpenoids and steroids in bile acid metabolism, transport, and signaling: Pharmacological and toxicological implications","volume":"14","author":"Luo","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"11","key":"10.1016\/j.bcp.2026.118225_b0550","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1021\/acs.jcim.5c00700","article-title":"A Unified Deep Graph Model for Identifying the Molecular Categories of Ligands Targeting Nuclear Receptors","volume":"65","author":"Yang","year":"2025","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bcp.2026.118225_b0555","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1016\/j.csbj.2021.04.029","article-title":"Farnesoid X receptor (FXR): Structures and ligands","volume":"19","author":"Jiang","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"6","key":"10.1016\/j.bcp.2026.118225_b0560","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1124\/pharmrev.121.000436","article-title":"International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily-Update 2023","volume":"75","author":"Burris","year":"2023","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bcp.2026.118225_b0565","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.658312","article-title":"Conformational Characterization of the Co-Activator Binding Site Revealed the Mechanism to Achieve the Bioactive State of FXR","volume":"8","author":"Kumari","year":"2021","journal-title":"Front. Mol. Biosci."},{"issue":"32","key":"10.1016\/j.bcp.2026.118225_b0570","doi-asserted-by":"crossref","first-page":"12535","DOI":"10.1074\/jbc.RA118.004188","article-title":"Structural insights into the heterodimeric complex of the nuclear receptors FXR and RXR","volume":"293","author":"Zheng","year":"2018","journal-title":"J. Biol. Chem."},{"issue":"25","key":"10.1016\/j.bcp.2026.118225_b0575","doi-asserted-by":"crossref","first-page":"7164","DOI":"10.1016\/j.cell.2024.10.001","article-title":"Structure-guided discovery of bile acid derivatives for treating liver diseases without causing itch","volume":"187","author":"Yang","year":"2024","journal-title":"Cell"},{"issue":"7834","key":"10.1016\/j.bcp.2026.118225_b0580","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41586-020-2569-1","article-title":"Structural basis of GPBAR activation and bile acid recognition","volume":"587","author":"Yang","year":"2020","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.bcp.2026.118225_b0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmr.2026.100120","article-title":"Gut microbiome and bile acid metabolism in liver disease: Mechanisms, clinical implications, and therapeutic opportunities","volume":"78","author":"Zhou","year":"2026","journal-title":"Pharmacol. Rev."},{"issue":"13","key":"10.1016\/j.bcp.2026.118225_b0590","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.3390\/nu14132707","article-title":"Enterohepatic Takeda G-Protein coupled Receptor 5 Agonism in Metabolic Dysfunction-Associated Fatty Liver Disease and Related Glucose Dysmetabolism","volume":"14","author":"Gillard","year":"2022","journal-title":"Nutrients"},{"issue":"9","key":"10.1016\/j.bcp.2026.118225_b0595","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.3390\/nu12092598","article-title":"TGR5 Signaling in Hepatic Metabolic Health","volume":"12","author":"Holter","year":"2020","journal-title":"Nutrients"},{"issue":"3","key":"10.1016\/j.bcp.2026.118225_b0600","doi-asserted-by":"crossref","first-page":"G412","DOI":"10.1152\/ajpgi.00300.2018","article-title":"Intestinal TGR5 agonism improves hepatic steatosis and insulin sensitivity in Western diet-fed mice","volume":"316","author":"Finn","year":"2019","journal-title":"American Journal of Physiology-gastrointestinal and Liver, Physiology"},{"issue":"10","key":"10.1016\/j.bcp.2026.118225_b0605","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3748\/wjg.v27.i10.959","article-title":"Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease","volume":"27","author":"Nadinskaia","year":"2021","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118225_b0610","doi-asserted-by":"crossref","first-page":"92","DOI":"10.5005\/jp-journals-10018-1434","article-title":"Ursodeoxycholic Acid\u2019s Effectiveness in the Management of Nonalcoholic Fatty Liver Disease: a Systematic Review and Meta-analysis","volume":"14","author":"Patel","year":"2024","journal-title":"Euroasian Journal of Hepatogastroenterology"},{"key":"10.1016\/j.bcp.2026.118225_b0615","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.174760","article-title":"Ursodesoxycholic acid is an FFA4 agonist and reduces hepatic steatosis via FFA4 signaling","volume":"917","author":"Xu","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118225_b0620","doi-asserted-by":"crossref","unstructured":"S. Marchian\u00f2, M. Biagioli, R. Roselli, A. Zampella, C.D. Giorgio, M. Bordoni, R. Bellini, G. Urbani, E. Morretta, M.C. Monti, E. Distrutti, S. Fiorucci, Beneficial effects of UDCA and norUDCA in a rodent model of steatosis are linked to modulation of GPBAR1\/FXR signaling, Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1867(11) (2022) 159218.","DOI":"10.1016\/j.bbalip.2022.159218"},{"issue":"3","key":"10.1016\/j.bcp.2026.118225_b0625","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/bph.14095","article-title":"Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease","volume":"175","author":"Wang","year":"2018","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118225_b0630","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1159\/000454853","article-title":"Therapeutic Mechanisms of Bile Acids and Nor-Ursodeoxycholic Acid in Non-Alcoholic Fatty Liver Disease","volume":"35","author":"Steinacher","year":"2017","journal-title":"Digestive Diseases (Basel, Switzerland)"},{"key":"10.1016\/j.bcp.2026.118225_b0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2023.117401","article-title":"Astragalus polysaccharide attenuates nonalcoholic fatty liver disease through THDCA in high-fat diet-fed mice","volume":"320","author":"Zheng","year":"2024","journal-title":"J. Ethnopharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118225_b0640","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41374-020-00509-x","article-title":"Stress can attenuate hepatic lipid accumulation via elevation of hepatic \u03b2-muricholic acid levels in mice with nonalcoholic steatohepatitis","volume":"101","author":"Takada","year":"2021","journal-title":"Laboratory Investigation; a Journal of Technical Methods and Pathology"},{"issue":"44","key":"10.1016\/j.bcp.2026.118225_b0645","doi-asserted-by":"crossref","first-page":"23058","DOI":"10.1074\/jbc.M116.731042","article-title":"Sevelamer Improves Steatohepatitis, Inhibits Liver and Intestinal Farnesoid X Receptor (FXR), and Reverses Innate Immune Dysregulation in a Mouse Model of Non-alcoholic Fatty Liver Disease","volume":"291","author":"McGettigan","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2026.118225_b0650","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s12072-022-10296-w","article-title":"Colesevelam ameliorates non-alcoholic steatohepatitis and obesity in mice","volume":"16","author":"Hartmann","year":"2022","journal-title":"Hep. Intl."},{"issue":"7","key":"10.1016\/j.bcp.2026.118225_b0655","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1872-034X.2009.00507.x","article-title":"Treatment of nonalcoholic steatohepatitis with colestimide","volume":"39","author":"Taniai","year":"2009","journal-title":"Hepatol. Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.118225_b0660","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41401-022-00921-7","article-title":"Caffeic acid phenethyl ester suppresses intestinal FXR signaling and ameliorates nonalcoholic fatty liver disease by inhibiting bacterial bile salt hydrolase activity","volume":"44","author":"Zhong","year":"2023","journal-title":"Acta Pharmacol. Sin."},{"issue":"34","key":"10.1016\/j.bcp.2026.118225_b0665","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abo2794","article-title":"Inhibition of microbial deconjugation of micellar bile acids protects against intestinal permeability and liver injury","volume":"8","author":"Li","year":"2022","journal-title":"Sci. Adv."},{"issue":"4","key":"10.1016\/j.bcp.2026.118225_b0670","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01155-21","article-title":"Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model mice","volume":"12","author":"Matsui","year":"2021","journal-title":"MBio"},{"issue":"11","key":"10.1016\/j.bcp.2026.118225_b0675","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nrgastro.2016.167","article-title":"NAFLD: Blocking ileal bile acid uptake safeguards against NAFLD","volume":"13","author":"Thomas","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bcp.2026.118225_b0680","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3389\/fmed.2020.00060","article-title":"Attenuation of the Hepatoprotective Effects of Ileal Apical Sodium Dependent Bile Acid Transporter (ASBT) Inhibition in Choline-Deficient L-Amino Acid-Defined (CDAA) Diet-Fed mice","volume":"7","author":"Rao","year":"2020","journal-title":"Front. Med."},{"key":"10.1016\/j.bcp.2026.118225_b0685","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ebiom.2018.10.030","article-title":"Dysregulated bile acid signaling contributes to the neurological impairment in murine models of acute and chronic liver failure","volume":"37","author":"Xie","year":"2018","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.bcp.2026.118225_b0690","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s12072-020-10107-0","article-title":"Elobixibat, an ileal bile acid transporter inhibitor, ameliorates non-alcoholic steatohepatitis in mice","volume":"15","author":"Yamauchi","year":"2021","journal-title":"Hep. Intl."},{"issue":"7","key":"10.1016\/j.bcp.2026.118225_b0695","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/s41401-018-0195-3","article-title":"A novel ASBT inhibitor, IMB17-15, repressed nonalcoholic fatty liver disease development in high-fat diet-fed Syrian golden hamsters","volume":"40","author":"Ge","year":"2018","journal-title":"Acta Pharmacol. Sin."},{"issue":"6","key":"10.1016\/j.bcp.2026.118225_b0700","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/cld.1076","article-title":"Obeticholic Acid for the Treatment of Nonalcoholic Steatohepatitis","volume":"17","author":"Ratziu","year":"2021","journal-title":"Clinical Liver Disease"},{"key":"10.1016\/j.bcp.2026.118225_b0705","article-title":"Discovery of a tricyclic farnesoid X receptor agonist HEC96719, a clinical candidate for treatment of non-alcoholic steatohepatitis","volume":"230","author":"Cao","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2026.118225_b0710","doi-asserted-by":"crossref","first-page":"e0039","DOI":"10.1097\/HC9.0000000000000039","article-title":"Sodium cholate ameliorates nonalcoholic steatohepatitis by activation of FXR signaling","volume":"7","author":"Pan","year":"2023","journal-title":"Hepatology Communications"},{"key":"10.1016\/j.bcp.2026.118225_b0715","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2025.119801","article-title":"Schisandra chinensis lignans ameliorate hepatic inflammation and steatosis in methionine choline-deficient diet-fed mice by modulating the gut-liver axis","volume":"348","author":"Yan","year":"2025","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.bcp.2026.118225_b0720","doi-asserted-by":"crossref","first-page":"115307","DOI":"10.1016\/j.ejmech.2023.115307","article-title":"Machine learning- and structure-based discovery of a novel chemotype as FXR agonists for potential treatment of nonalcoholic fatty liver disease","volume":"252","author":"Tong","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bcp.2026.118225_b0725","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.cmet.2021.06.012","article-title":"FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption","volume":"33","author":"Clifford","year":"2021","journal-title":"Cell Metab."},{"issue":"6","key":"10.1016\/j.bcp.2026.118225_b0730","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1002\/ptr.7055","article-title":"Isotschimgine alleviates nonalcoholic steatohepatitis and fibrosis via FXR agonism in mice","volume":"35","author":"Li","year":"2021","journal-title":"Phytotherapy Research : PTR"},{"key":"10.1016\/j.bcp.2026.118225_b0735","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.phymed.2018.09.006","article-title":"Yangonin protects against non-alcoholic fatty liver disease through farnesoid X receptor","volume":"53","author":"Dong","year":"2019","journal-title":"Phytomedicine"},{"issue":"13","key":"10.1016\/j.bcp.2026.118225_b0740","first-page":"2492","article-title":"Ginsenoside Rh4 Improves Hepatic Lipid Metabolism and Inflammation in a Model of NAFLD by Targeting the Gut Liver Axis and Modulating the FXR Signaling Pathway","volume":"12","author":"Yang","year":"2023","journal-title":"Foods (Basel, Switzerland)"},{"key":"10.1016\/j.bcp.2026.118225_b0745","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.phrs.2017.04.021","article-title":"Cycloastragenol improves hepatic steatosis by activating farnesoid X receptor signalling","volume":"121","author":"Gu","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2026.118225_b0750","article-title":"Improvement of NASH and liver fibrosis through modulation of the gut-liver axis by a novel intestinal FXR agonist","volume":"173","author":"Moon","year":"2024","journal-title":"Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie"},{"issue":"20","key":"10.1016\/j.bcp.2026.118225_b0755","doi-asserted-by":"crossref","first-page":"7723","DOI":"10.1021\/acs.jafc.3c00952","article-title":"Dietary Isoquercetin Reduces Hepatic Cholesterol and Triglyceride in NAFLD mice by Modulating Bile Acid Metabolism via Intestinal FXR-FGF15 Signaling","volume":"71","author":"Zhang","year":"2023","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.bcp.2026.118225_b0760","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.154444","article-title":"Astragaloside IV ameliorates diet-induced hepatic steatosis in obese mice by inhibiting intestinal FXR via intestinal flora remodeling","volume":"107","author":"Zhai","year":"2022","journal-title":"Phytomedicine : International Journal of Phytotherapy and Phytopharmacology"},{"issue":"19","key":"10.1016\/j.bcp.2026.118225_b0765","doi-asserted-by":"crossref","first-page":"13452","DOI":"10.1021\/acs.jmedchem.2c01394","article-title":"Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis","volume":"65","author":"Zhang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118225_b0770","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2025.130222","article-title":"Discovery of farnesoid X receptor antagonists from Salvia miltiorrhiza based on virtual screening and activity verification","volume":"123","author":"Tu","year":"2025","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"1","key":"10.1016\/j.bcp.2026.118225_b0775","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1172\/JCI76738","article-title":"Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease","volume":"125","author":"Jiang","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.bcp.2026.118225_b0780","doi-asserted-by":"crossref","first-page":"113","DOI":"10.7150\/ijbs.87305","article-title":"The Role of Nuclear Receptors in the Pathogenesis and Treatment of Non-alcoholic Fatty Liver Disease","volume":"20","author":"Yang","year":"2024","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.bcp.2026.118225_b0785","doi-asserted-by":"crossref","unstructured":"C. Jiang, C. Xie, Y. Lv, J. Li, K.W. Krausz, J. Shi, C.N. Brocker, D. Desai, S.G. Amin, W.H. Bisson, Y. Liu, O. Gavrilova, A.D. Patterson, FJ, Gonzalez, Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction, Nature communications 6 (2015) 10166.","DOI":"10.1038\/ncomms10166"},{"issue":"1","key":"10.1016\/j.bcp.2026.118225_b0790","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1038\/s41467-020-17363-6","article-title":"An FGF15\/19-TFEB regulatory loop controls hepatic cholesterol and bile acid homeostasis","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bcp.2026.118225_b0795","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1038\/s41467-019-12896-x","article-title":"Theabrownin from Pu-erh tea attenuates hypercholesterolemia via modulation of gut microbiota and bile acid metabolism","volume":"10","author":"Huang","year":"2019","journal-title":"Nat. Commun."},{"issue":"21","key":"10.1016\/j.bcp.2026.118225_b0800","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.bcp.2026.118225_b0805","doi-asserted-by":"crossref","first-page":"10675","DOI":"10.1039\/D0FO01954B","article-title":"Amelioration of non-alcoholic fatty liver disease by sodium butyrate is linked to the modulation of intestinal tight junctions in db\/db mice","volume":"11","author":"Yang","year":"2020","journal-title":"Food Funct"},{"key":"10.1016\/j.bcp.2026.118225_b0810","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2026.121451","article-title":"Integrated metabolomic and transcriptomic analyses reveal Radix Bupleuri alleviates MASLD induced by a high-fat diet and circadian disruption via the DCA\/HCA-TGR5-GLP-1 axis","volume":"363","author":"Wang","year":"2026","journal-title":"J. Ethnopharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118225_b0815","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.3390\/ijms27041947","article-title":"Discovery of Obacunone as a TGR5 Agonist from Rhizoma coptidis\u202f: Affinity Screening, Functional Verification and Transcriptional Analysis","volume":"27","author":"Fu","year":"2026","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.118225_b0820","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/nu11010077","article-title":"Beneficial Effects of Vitamin D Treatment in an Obese Mouse Model of Non-Alcoholic Steatohepatitis","volume":"11","author":"Jahn","year":"2019","journal-title":"Nutrients"},{"issue":"5","key":"10.1016\/j.bcp.2026.118225_b0825","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/hep.30937","article-title":"Vitamin D Receptor Activation in Liver Macrophages Ameliorates Hepatic Inflammation, Steatosis, and Insulin Resistance in mice","volume":"71","author":"Dong","year":"2020","journal-title":"Hepatology"},{"issue":"19","key":"10.1016\/j.bcp.2026.118225_b0830","doi-asserted-by":"crossref","first-page":"20561","DOI":"10.1021\/acs.jmedchem.5c01753","article-title":"Design, Synthesis, and Evaluation of Antifibrotic activity of Nonsteroidal VDR Agonists Featuring 1,6-Naphthol as a CD-Ring Surrogate","volume":"68","author":"Gao","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118225_b0835","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117250","article-title":"Design, synthesis, and anti-liver fibrosis activity of novel non-steroidal vitamin D receptor agonists based on open-ring steroid scaffold","volume":"286","author":"Gao","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118225_b0840","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2026.118592","article-title":"Design, synthesis, and anti-liver fibrosis activity of novel non-steroidal vitamin D receptor agonists based on phenyl-indole scaffold","volume":"306","author":"Tong","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118225_b0845","doi-asserted-by":"crossref","unstructured":"T.S. Tai, N. Tien, H.Y. Shen, F.Y. Chu, Charles, C. N. Wang, Chieh\u2010Hsiang, Lu, Hui, I. Yu, Fang-Ping, Kung, Hsiang-Hsun, Chuang, Ying\u2010Ray, Lee, Horng-Jinh, Chang, Yun-Ping, Lim, Sesamin, a Naturally Occurring Lignan, Inhibits Ligand-Induced Lipogenesis through Interaction with Liver X Receptor Alpha (LXR\u03b1) and Pregnane X Receptor (PXR), Evidence-based Complementary and Alternative Medicine 2019 (2019) 9401648.","DOI":"10.1155\/2019\/9401648"},{"issue":"19","key":"10.1016\/j.bcp.2026.118225_b0850","doi-asserted-by":"crossref","first-page":"17608","DOI":"10.1021\/acs.jmedchem.4c01597","article-title":"Discovery of N -Aryl- N \u2019- 4-(aryloxy)cyclohexyl squaramide-based Inhibitors of LXR\/SREBP-1c Signaling Pathway Ameliorating Steatotic Liver Disease: Navigating the Role of SIRT6 Activation","volume":"67","author":"Nguyen","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118225_b0855","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156054","article-title":"Hepatocyte-specific SLC27A4 deletion ameliorates nonalcoholic fatty liver disease in mice via suppression of phosphatidylcholine-mediated PXR activation","volume":"162","author":"Shen","year":"2025","journal-title":"Metab. Clin. Exp."},{"key":"10.1016\/j.bcp.2026.118225_b0860","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2024.119199","article-title":"Cassia mimosoides L. decoction improves non-alcoholic fatty liver disease by modulating the pregnane X receptor","volume":"340","author":"Zhao","year":"2025","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.bcp.2026.118225_b0865","article-title":"Pregnane X receptor antagonist MI-891 reduces hepatic triglycerides in PXR-CAR-CYP3A4\/3A7-humanized mice","volume":"197","author":"Dohnalov\u00e1","year":"2026","journal-title":"Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie"},{"issue":"1","key":"10.1016\/j.bcp.2026.118225_b0870","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1021\/acs.molpharmaceut.2c00549","article-title":"Engineered Fenofibrate as Oxidation-Sensitive Nanoparticles with ROS Scavenging and PPAR\u03b1-Activating Bioactivity to Ameliorate Nonalcoholic Fatty Liver Disease","volume":"20","author":"Du","year":"2023","journal-title":"Mol. Pharm."},{"issue":"5","key":"10.1016\/j.bcp.2026.118225_b0875","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1021\/acs.jnatprod.2c00990","article-title":"Dihydrotrichodimerol Purified from the Marine Fungus Acremonium citrinum Prevents NAFLD by Targeting PPAR\u03b1","volume":"86","author":"Liu","year":"2023","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.bcp.2026.118225_b0880","doi-asserted-by":"crossref","unstructured":"J. Creeden, D.M. Gordon, D.F. Stec, M.C. Donald, Z.L. Mitchell, A.J. Morris, D.E. Stec, T.D. Hinds, Bilirubin nanoparticles activate PPARalpha to remodel the hepatic lipidome and produce hepatic ketones in obese mice, improving liver function, FASEB J. 35(S1) (2021) 01992.","DOI":"10.1096\/fasebj.2021.35.S1.01992"},{"key":"10.1016\/j.bcp.2026.118225_b0885","doi-asserted-by":"crossref","unstructured":"J.W. Shou, J. Ma, X. Wang, X.X. Li, S.C. Chen, B.H. Kang, P.C. Shaw, Free Cholesterol-Induced Liver Injury in Non-Alcoholic Fatty Liver Disease: Mechanisms and a Therapeutic Intervention Using Dihydrotanshinone I, Advanced science (Weinheim, Baden-Wurttemberg, Germany) 12(2) (2025) e2406191.","DOI":"10.1002\/advs.202406191"},{"key":"10.1016\/j.bcp.2026.118225_b0890","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.177173","article-title":"Oxymatrine relieves non-alcoholic fatty liver disease by promoting sirtuin 1\/adenosine 5'-monophosphate-activated protein kinase pathway and peroxisome proliferator activated receptor alpha-mediated hepatic fatty acid oxidation","volume":"987","author":"Wu","year":"2025","journal-title":"Eur. J. Pharmacol."},{"issue":"23","key":"10.1016\/j.bcp.2026.118225_b0895","doi-asserted-by":"crossref","first-page":"5847","DOI":"10.1111\/bph.70161","article-title":"\u03b2-elemene ameliorates metabolic dysfunction-associated steatohepatitis by targeting PPAR\u03b1 in experimental diet-induced models","volume":"182","author":"Xiong","year":"2025","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118225_b0900","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/hep.23727","article-title":"High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Leuschner","year":"2010","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"12","key":"10.1016\/j.bcp.2026.118225_b0905","doi-asserted-by":"crossref","DOI":"10.4254\/wjh.v17.i12.113658","article-title":"Phase III, multicenter, randomized, double-blind, placebo-controlled study of norursodeoxycholic acid in metabolic dysfunction-associated steatotic liver disease patients","volume":"17","author":"Panuganti","year":"2025","journal-title":"World J. Hepatol."},{"issue":"16","key":"10.1016\/j.bcp.2026.118225_b0910","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1001\/archinte.159.16.1893","article-title":"Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects","volume":"159","author":"Davidson","year":"1999","journal-title":"Arch. Intern. Med."},{"issue":"10","key":"10.1016\/j.bcp.2026.118225_b0915","doi-asserted-by":"crossref","first-page":"971","DOI":"10.4065\/76.10.971","article-title":"Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial","volume":"76","author":"Insull","year":"2001","journal-title":"Mayo Clin. Proc."},{"issue":"3","key":"10.1016\/j.bcp.2026.118225_b0920","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/hep.25731","article-title":"Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial","volume":"56","author":"Le","year":"2012","journal-title":"Hepatology (Baltimore Md.)"},{"key":"10.1016\/j.bcp.2026.118225_b0925","doi-asserted-by":"crossref","unstructured":"A. Rao, A. Kosters, J.E. Mells, W.J. Zhang, K.D. R. Setchell, A.M. Amanso, G.M. Wynn, T.L. Xu, B.T. Keller, H. Yin, S. Banton, D.P. Jones, H. Wu, P.A. Dawson, S.J. Karpen, Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice, Science translational medicine 8(357) (2016) 357ra122.","DOI":"10.1126\/scitranslmed.aaf4823"},{"issue":"6","key":"10.1016\/j.bcp.2026.118225_b0930","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.jhep.2019.08.005","article-title":"Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development","volume":"71","author":"Mouries","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bcp.2026.118225_b0935","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.2147\/DDDT.S207277","article-title":"The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease","volume":"13","author":"Zhang","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"issue":"7","key":"10.1016\/j.bcp.2026.118225_b0940","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000037271","article-title":"The effect and safety of obeticholic acid for patients with nonalcoholic steatohepatitis: a systematic review and meta-analysis of randomized controlled trials","volume":"103","author":"Zhao","year":"2024","journal-title":"Medicine"},{"key":"10.1016\/j.bcp.2026.118225_b0945","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/6171658","article-title":"Schisandrin B: a Double-Edged Sword in Nonalcoholic Fatty Liver disease","volume":"2016","author":"Leong","year":"2016","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"47","key":"10.1016\/j.bcp.2026.118225_b0950","doi-asserted-by":"crossref","first-page":"6165","DOI":"10.3748\/wjg.v29.i47.6165","article-title":"Liver decompensation after rapid weight loss from semaglutide in a patient with non-alcoholic steatohepatitis -associated cirrhosis","volume":"29","author":"Peverelle","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bcp.2026.118225_b0955","doi-asserted-by":"crossref","unstructured":"M. Bjelakovi\u0107, D. Nikolova, G. Bjelakovi\u0107, C. Gluud, Vitamin D supplementation for chronic liver diseases in adults, The Cochrane database of systematic reviews 2021(8) (2021) CD011564.","DOI":"10.1002\/14651858.CD011564.pub3"},{"issue":"5","key":"10.1016\/j.bcp.2026.118225_b0960","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.1002\/mco2.354","article-title":"Nano-calcipotriol as a potent anti-hepatic fibrosis agent","volume":"4","author":"Zhang","year":"2023","journal-title":"MedComm"},{"key":"10.1016\/j.bcp.2026.118225_b0965","doi-asserted-by":"crossref","unstructured":"Z.Y. Wang, C.R. Ma, Y.N. Shang, L.J. Yang, J. Zhang, C.H. Yang, C.H. Ren, J.J. Liu, G.W. Fan, J.F. Liu, Simultaneous co-assembly of fenofibrate and ketoprofen peptide for the dual-targeted treatment of nonalcoholic fatty liver disease (NAFLD), Chemical communications (Cambridge, England) 56(36) (2020) 4922\u20134925.","DOI":"10.1039\/D0CC00513D"},{"issue":"8","key":"10.1016\/j.bcp.2026.118225_b0970","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1016\/j.drudis.2022.05.007","article-title":"Impact of fenofibrate on NAFLD\/NASH: a genetic perspective","volume":"27","author":"Mahmoudi","year":"2022","journal-title":"Drug Discov. Today"},{"issue":"5","key":"10.1016\/j.bcp.2026.118225_b0975","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmr.2025.100073","article-title":"Pathological and therapeutic roles of bile acid metabolism and signaling in hepatocellular carcinoma: Insights from human and mouse studies","volume":"77","author":"Wang","year":"2025","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bcp.2026.118225_b0980","doi-asserted-by":"crossref","DOI":"10.1016\/j.plipres.2024.101291","article-title":"Immunology of bile acids regulated receptors","volume":"95","author":"Fiorucci","year":"2024","journal-title":"Prog. Lipid Res."},{"issue":"11","key":"10.1016\/j.bcp.2026.118225_b0985","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1113\/JP281727","article-title":"Bile acids, bioactive signalling molecules in interoceptive gut-to-brain communication","volume":"600","author":"Joyce","year":"2022","journal-title":"J. Physiol."},{"key":"10.1016\/j.bcp.2026.118225_b0990","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116658","article-title":"A Current Understanding of FXR in NAFLD: the multifaceted regulatory role of FXR and novel lead discovery for drug development","volume":"175","author":"Tang","year":"2024","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"16","key":"10.1016\/j.bcp.2026.118225_b0995","doi-asserted-by":"crossref","first-page":"12181","DOI":"10.1021\/acs.jmedchem.1c00851","article-title":"Identification of Betulinic Acid Derivatives as Potent TGR5 Agonists with Antidiabetic Effects via Humanized TGR5 H88Y Mutant mice","volume":"64","author":"Yun","year":"2021","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2026.118225_b1000","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1210\/mend.14.1.0409","article-title":"The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution","volume":"14","author":"Jones","year":"2000","journal-title":"Molecular endocrinology (Baltimore, Md.)"},{"issue":"19","key":"10.1016\/j.bcp.2026.118225_b1005","doi-asserted-by":"crossref","first-page":"17277","DOI":"10.1074\/jbc.M300138200","article-title":"Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes","volume":"278","author":"Maglich","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.bcp.2026.118225_b1010","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1128\/MCB.20.9.2951-2958.2000","article-title":"The xenobiotic compound 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene is an agonist ligand for the nuclear receptor CAR","volume":"20","author":"Tzameli","year":"2000","journal-title":"Mol. Cell. Biol."},{"issue":"20","key":"10.1016\/j.bcp.2026.118225_b1015","doi-asserted-by":"crossref","first-page":"15122","DOI":"10.1074\/jbc.M001215200","article-title":"Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands","volume":"275","author":"Moore","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2026.118225_b1020","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3390\/biom15040579","article-title":"Exploring the Roles of Liver X Receptors in Lipid Metabolism and Immunity in Atherosclerosis","volume":"15","author":"Endo-Umeda","year":"2025","journal-title":"Biomolecules"},{"issue":"5","key":"10.1016\/j.bcp.2026.118225_b1025","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1210\/endrev\/bnae009","article-title":"Consensus Statement on Vitamin D Status Assessment and Supplementation: Whys, Whens, and Hows","volume":"45","author":"Giustina","year":"2024","journal-title":"Endocrine Reviews"},{"key":"10.1016\/j.bcp.2026.118225_b1030","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jconrel.2024.07.008","article-title":"A novel chemically engineered multifunctional statin conjugate as self-assembled nanoparticles inhibiting bile acid transporters","volume":"372","author":"Lee","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bcp.2026.118225_b1035","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122539","article-title":"Design and development of novel self-assembled catechol-modified bile acid conjugates as pH-responsive apical sodium-dependent bile acid transporter targeting nanoparticles","volume":"308","author":"Lee","year":"2024","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.bcp.2026.118225_b1040","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1038\/s41467-021-25701-5","article-title":"A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes","volume":"12","author":"Harrison","year":"2021","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.bcp.2026.118225_b1045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2021.100237","article-title":"Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis","volume":"3","author":"Bhattacharya","year":"2021","journal-title":"JHEP Reports : Innovation in Hepatology"},{"key":"10.1016\/j.bcp.2026.118225_b1050","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1476-511X-13-69","article-title":"L-arginine conjugates of bile acids-a possible treatment for non-alcoholic fatty liver disease","volume":"13","author":"Voloshin","year":"2014","journal-title":"Lipids Health Dis."},{"issue":"11","key":"10.1016\/j.bcp.2026.118225_b1055","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1016\/j.cell.2024.03.034","article-title":"Gut symbionts alleviate MASH through a secondary bile acid biosynthetic pathway","volume":"187","author":"Nie","year":"2024","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.bcp.2026.118225_b1060","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.3390\/nu11051132","article-title":"Transcriptome Analysis of dual FXR and GPBAR1 Agonism in Rodent Model of NASH reveals Modulation of Lipid Droplets Formation","volume":"11","author":"Carino","year":"2019","journal-title":"Nutrients"},{"issue":"12","key":"10.1016\/j.bcp.2026.118225_b1065","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1002\/ptr.6486","article-title":"Quercetin improves nonalcoholic fatty liver by ameliorating inflammation, oxidative stress, and lipid metabolism in db\/db mice","volume":"33","author":"Yang","year":"2019","journal-title":"Phytotherapy Research : PTR"},{"key":"10.1016\/j.bcp.2026.118225_b1070","doi-asserted-by":"crossref","unstructured":"J. Liu, Y. Liu, C. Huang, C. He, T. Yang, R. Ren, Z. Xin, X. Wang, Quercetin-Driven Akkermansia Muciniphila Alleviates Obesity by Modulating Bile Acid Metabolism via an ILA\/m 6 A\/CYP8B1 Signaling, Advanced science (Weinheim, Baden-Wurttemberg, Germany) 12(12) (2025) e2412865.","DOI":"10.1002\/advs.202412865"},{"issue":"7","key":"10.1016\/j.bcp.2026.118225_b1075","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1002\/ptr.7770","article-title":"Deoxyschizandrin ameliorates obesity and non-alcoholic fatty liver disease: Involvement of dual Farnesyl X receptor\/G protein-coupled bile acid receptor 1 activation and leptin sensitization","volume":"37","author":"Gu","year":"2023","journal-title":"Phytotherapy Research : PTR"},{"issue":"Pt 4","key":"10.1016\/j.bcp.2026.118225_b1080","article-title":"Salidroside attenuates NASH through regulating bile acid-FXR\/TGR5 signaling pathway via targeting gut microbiota","volume":"307","author":"Zhang","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bcp.2026.118225_b1085","article-title":"Effects of flaxseed powder in improving non-alcoholic fatty liver by regulating gut microbiota-bile acids metabolic pathway through FXR\/TGR5 mediating","volume":"163","author":"Yang","year":"2023","journal-title":"Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie"},{"key":"10.1016\/j.bcp.2026.118225_b1090","doi-asserted-by":"crossref","unstructured":"V.D. Shiragannavar, N.G.S. Gowda, L.D. Puttahanumantharayappa, S.H. Karunakara, S.S. Bhat, S.K. Prasad, D.P. Kumar, P.K. Santhekadur, The ameliorating effect of withaferin A on high-fat diet-induced non-alcoholic fatty liver disease by acting as an LXR\/FXR dual receptor activator, Frontiers in pharmacology 14 (2023) 1135952.","DOI":"10.3389\/fphar.2023.1135952"},{"key":"10.1016\/j.bcp.2026.118225_b1095","doi-asserted-by":"crossref","first-page":"934136","DOI":"10.3389\/fphar.2022.934136","article-title":"Dapagliflozin protects against nonalcoholic steatohepatitis in db\/db mice","volume":"13","author":"Qiao","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.bcp.2026.118225_b1100","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.1021\/acs.jmedchem.2c01918","article-title":"Discovery of the First-in-Class Intestinal Restricted FXR and FABP1 dual Modulator ZLY28 for the Treatment of Nonalcoholic Fatty Liver Disease","volume":"66","author":"Ren","year":"2023","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2026.118225_b1105","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/s41598-023-28647-4","article-title":"Combinatorial therapy with BAR502 and UDCA resets FXR and GPBAR1 signaling and reverses liver histopathology in a model of NASH","volume":"13","author":"Marchian\u00f2","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2026.118225_b1110","doi-asserted-by":"crossref","unstructured":"S.H. Seo, D.H. Lee, Y.S. Lee, K.J. Cho, H.J. Park, H.W. Lee, S.U. Kim, J.Y. Park, D.Y. Kim, S.H. Ahn, S.H. Bae, S.U. Kim, Co-administration of ursodeoxycholic acid with rosuvastatin\/ezetimibe in a non-alcoholic fatty liver disease model, Gastroenterology Report 10 (2022).","DOI":"10.1093\/gastro\/goac037"},{"key":"10.1016\/j.bcp.2026.118225_b1115","doi-asserted-by":"crossref","unstructured":"Z.X. Ying, Robin van, Eenige, Xiaoke, Ge, Christy van, Marwijk, Joost, M. Lambooij, Bruno, Guigas, Martin, Giera, Jan Freark de, Boer, Tamer, Co\u015fkun, Hongchang, Qu, Yanan, Wang, Mari\u00ebtte, R. Boon, Patrick, C. N. Rensen, Sander, Kooijman, Combined GIP receptor and GLP1 receptor agonism attenuates NAFLD in male APOE\u22173-Leiden.CETP mice, EBioMedicine 93 (2023) 104684.","DOI":"10.1016\/j.ebiom.2023.104684"},{"key":"10.1016\/j.bcp.2026.118225_b1120","doi-asserted-by":"crossref","unstructured":"J. Norlin, D.A. Miranda, J. Bates, N.E. Zois, S.S. Veidal, M. Feigh, J.L. Trevaskis, M. Latta, 1810-P: Triple Combination Therapy of GLP-1 Receptor Agonist Semaglutide with an FXR Agonist and AC Inhibitor Reverses Nonalcoholic Steatohepatitis (NASH) in Diet-Induced and Biopsy-Confirmed Mice, Diabetes (2020).","DOI":"10.2337\/db20-1810-P"},{"issue":"3","key":"10.1016\/j.bcp.2026.118225_b1125","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jcmgh.2021.04.013","article-title":"Combined ASBT Inhibitor and FGF15 Treatment Improves Therapeutic Efficacy in Experimental Nonalcoholic Steatohepatitis","volume":"12","author":"Matye","year":"2021","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118225_b1130","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2024.108932","article-title":"The effect of semaglutide combined with metformin on liver inflammation and pancreatic beta-cell function in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"39","author":"Ren","year":"2025","journal-title":"J. Diabetes Complications"},{"key":"10.1016\/j.bcp.2026.118225_b1135","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120956","article-title":"Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms","volume":"308","author":"Shaaban","year":"2022","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.118225_b1140","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12951-021-00979-1","article-title":"Improving the ameliorative effects of berberine and curcumin combination via dextran-coated bilosomes on non-alcohol fatty liver disease in mice","volume":"19","author":"Chen","year":"2021","journal-title":"J. Nanobiotechnol."},{"issue":"12","key":"10.1016\/j.bcp.2026.118225_b1145","article-title":"The Synbiotic Combination of Akkermansia muciniphila and Quercetin Ameliorates Early Obesity and NAFLD through Gut Microbiota Reshaping and Bile Acid Metabolism Modulation","volume":"10","author":"Ju\u00e1rez-Fern\u00e1ndez","year":"2021","journal-title":"Antioxidants (Basel, Switzerland)"},{"key":"10.1016\/j.bcp.2026.118225_b1150","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bbrc.2021.12.065","article-title":"Hepatoprotective effects of gemigliptin and empagliflozin in a murine model of diet-induced non-alcoholic fatty liver disease","volume":"588","author":"Lee","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"11","key":"10.1016\/j.bcp.2026.118225_b1155","doi-asserted-by":"crossref","first-page":"102530","DOI":"10.1016\/j.jbc.2022.102530","article-title":"The role of FXR and TGR5 in reversing and preventing progression of Western diet-induced hepatic steatosis, inflammation, and fibrosis in mice","volume":"298","author":"Wang","year":"2022","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2026.118225_b1160","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ajcnut.2024.07.013","article-title":"Quercetin intervention reduced hepatic fat deposition in patients with nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled crossover clinical trial","volume":"120","author":"Li","year":"2024","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.bcp.2026.118225_b1165","article-title":"Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial","volume":"389","author":"Lin","year":"2025","journal-title":"BMJ (clinical Research Ed.)"},{"issue":"10","key":"10.1016\/j.bcp.2026.118225_b1170","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"issue":"Suppl 2","key":"10.1016\/j.bcp.2026.118225_b1175","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1007\/s12072-024-10660-y","article-title":"MAFLD as part of systemic metabolic dysregulation","volume":"18","author":"Zhao","year":"2024","journal-title":"Hep. Intl."},{"key":"10.1016\/j.bcp.2026.118225_b1180","doi-asserted-by":"crossref","unstructured":"E. Kaffe, M. Roulis, J. Zhao, R.H. Qu, E. Sefik, H. Mirza, J. Zhou, Y.J. Zheng, G. Charkoftaki, V. Vasiliou, D.F. Vatner, W.Z. Mehal, Y. Kluger, Ri.A. Flavell, Humanized mouse liver reveals endothelial control of essential hepatic metabolic functions, Cell 186(18) (2023) 3793-3809.","DOI":"10.1016\/j.cell.2023.07.017"},{"key":"10.1016\/j.bcp.2026.118225_b1185","doi-asserted-by":"crossref","unstructured":"L. Wang, Y. Koui, K. Kanegae, T. Kido, M. Tamura-Nakano, S. Yabe, K. Tai, Y. Nakajima, H, Kusuhara, Y, Sakai, A, Miyajima, H, Okochi, M, Tanaka, Establishment of human induced pluripotent stem cell-derived hepatobiliary organoid with bile duct for pharmaceutical research use, Biomaterials 310 (2024) 122621.","DOI":"10.1016\/j.biomaterials.2024.122621"},{"issue":"9","key":"10.1016\/j.bcp.2026.118225_b1190","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/s41575-024-00915-2","article-title":"Spatial genomics: mapping human steatotic liver disease","volume":"21","author":"Matchett","year":"2024","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bcp.2026.118225_b1195","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2025.108785","article-title":"Integrating multi-omics and artificial intelligence fuels advanced target identification and drug discovery","volume":"87","author":"Chen","year":"2026","journal-title":"Biotechnol. Adv."},{"issue":"12","key":"10.1016\/j.bcp.2026.118225_b1200","article-title":"Metabolomics at the cutting edge of risk prediction of MASLD","volume":"5","author":"Tan","year":"2024","journal-title":"Cell Rep. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118225_b1205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10822-017-0088-4","article-title":"D3R Grand Challenge 2: blind prediction of protein-ligand poses, affinity rankings, and relative binding free energies","volume":"32","author":"Gaieb","year":"2018","journal-title":"J. Comput. Aided Mol. Des."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226005642?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226005642?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:19:18Z","timestamp":1786652358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226005642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":241,"alternative-id":["S0006295226005642"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118225","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dysregulation of the bile acid signaling network in non-alcoholic fatty liver disease: Mechanisms and a new paradigm of precision network pharmacology","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118225","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118225"}}